Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 962 of 6351
-
New heart valve implant could offer hope for leaky aortic valve patients
Disease control Recruiting nowProspective, multicenter, randomized trial.
Sponsor: Nanjing First Hospital, Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New Dual-Action drug shows promise in advanced lung cancer trial
Disease control CompletedThis trial is a Phase Ib/II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in subjects with advanced NSCLC wh…
Phase 1/2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Group prenatal care may ease depression and prevent preterm birth in black mothers
Symptom relief OngoingThis study will provide high-quality, representative data on the capacity of Elevating Voices, Addressing Depression, Toxic Stress and Equity in Group Prenatal Care (EleVATE GC) to reduce perinatal depression, preterm birth, and low birthweight in African-American women. If findi…
Sponsor: Washington University School of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Can an arthritis drug help fight lung cancer?
Disease control CompletedThe researchers are doing this study to find out whether canakinumab in combination with chemoradiation and durvalumab is an effective and safe treatment for people with locally advanced non-small cell lung cancer (NSCLC).
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a simple shot replace IV drips for kidney cancer patients?
Disease control OngoingThe purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread. The purpose of this study's …
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New combo therapy targets liver metastases in hard-to-treat cancers
Disease control Recruiting nowPatients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Phase 2 • Sponsor: Teclison Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can brain recordings unlock better OCD treatment?
Knowledge-focused OngoingObsessive-compulsive disorder effects approximately 2-3% of the population. The only established first-line treatments for OCD are cognitive-behavioral therapy (CBT) with exposure/response prevention and serotonin reuptake inhibitor medications (SRIs). Approximately 30-40% of pat…
Sponsor: Baylor College of Medicine • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Triple-Drug cocktail shows promise for tough bladder cancer
Disease control Recruiting nowPhase I of this research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic urothelial carcinoma (mUC). In Phase II of the study, patients in one of the two cohorts will receive Sacituzumab Govitecan,…
Phase 1/2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo therapy aims to extend remission in elderly lymphoma patients
Disease control OngoingThis phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-miniCHOP\]) versus R-miniCHOP alone in treating patients 75 year…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New triple therapy shows promise for aggressive lung cancer
Disease control CompletedSmall Cell Lung cancer (SCLC) is a highly aggressive tumor that accounts for about 15 percent of all lung cancer cases. SCLC disease progresses rapidly, and about 2/3 of the patients have extensive stage (ES-SCLC) at the time of diagnosis, with extremely poor prognosis. However, …
Phase 2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Stem cell eye transplant aims to halt blindness from rare genetic disease
Disease control OngoingThis project intends to transplant a clinical level human embryonic stem cells derived retinal pigment epithelium into subretinal space to treat eetinitis pigmentosa(RP) diseases. Through the statistical analysis EDTRS, BCVA, OCT, ERG, Fluorescein angiography, Ophthalmic AB ultra…
Phase 1 • Sponsor: Qi Zhou • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New hope for Alzheimer's? drug targets High-Risk gene carriers
Disease control CompletedThis study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.
Phase 3 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New pill shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThe purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to eval…
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New vaccine combo shows promise for hard-to-treat melanoma
Disease control CompletedThis is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-programmed death protein 1 (PD-1)/anti-programmed death ligand 1 (PD-L1)-refractory/relapsed patients with unre…
Phase 2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug cocktail shows promise in battling bone marrow cancer
Disease control OngoingThis research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and…
Phase 1/2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could a strong social circle turn back the clock for transplant survivors?
Knowledge-focused Recruiting nowThis project aims to elucidate the important protective elements of social relationships and identify concrete, modifiable behavioral factors that contribute to biological and phenotypic aging in hematopoietic cell transplantation (HCT) survivors and can be used to develop biolog…
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Diabetes drug semaglutide tested as potential Alzheimer's treatment
Disease control CompletedThis study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided …
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Diabetes drug semaglutide put to the test against Alzheimer's in major trial
Disease control CompletedThis study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided …
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental CAR t therapy targets tough leukemia in first human trial
Disease control OngoingA Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Phase 1 • Sponsor: PeproMene Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Targeted pill shows promise for rare lung cancer mutation in chinese patients
Disease control CompletedThe purpose of the study was to learn whether the study treatment (capmatinib), which already shows efficacy and safety in non-Chinese patients, could help Chinese patients with controlling their lung cancer in a safe way. Participants had a type of lung cancer called non-small c…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC